PharmaTalkRadio

Originally recorded at the 4th annual Immuno-Oncology 360° 2018 event, Dr Corey Langer, Director, Thoracic Oncology and Professor of Medicine for the Perelman Center for Advanced Medicine at the University of Pennsylvania, discusses data on Keytruda in combination with chemotherapy in non-small cell lung cancer.

This year, the University of Pennsylvania will be represented by Dr Marco Ruella, Assistant Professor and Scientific Director Lymphoma Program, Division of Hematology and Oncology, Department of Medicine and Center for Cellular Immunotherapies. Dr Ruella will be discussing the next steps for CAR-T therapy for cancer on day three during the Next Generation Cell Therapy Plenary

To join in on the discussion at the 5th annual IO360 conference taking place February 6-8, 2019 in New York, NY!

In this podcast, originally recorded at the 4th annual annual Immuno-Oncology 360° 2018 event, Dr Axel Hoos, SVP, Oncology R&D, GSK, led a panel on The Future Value Generation in IO. Dr Hoos was joined by expert analyst Dr Andrew Baum, Head of Global Healthcare and Managing Director of Equity Research for Citi along with Dr David Grayzel, Partner of Atlas Venture, Dr Simeon George, Partner of SR One and Mark Simon, Partner of Torreya Partners. Key discussion points included:

What is the most important IO event or trend that will carry us forward and shape the IO space?With the ever expanding range of indications, what is next and how do we get there?What have we learned from precision medicine and how can that be applied to IO?Which biomarker is next that will follow PDL1 and that will help guide the field in patient selection?With the many opportunities now with modalities, what do you think is a valuable next modality that could be important?With the maturing and evolving IO landscape, has that changed investment sentiment?   

For the latest news in immunotherapy, join us at the 5th annual IO360 conference taking place February 6-8, 2019 in New York, NY.

Greg Simon, President at the Biden Cancer Initiative and Former Executive Director of the White House Cancer Task Force will reflect on the work of the Cancer Moonshot. Which provided the leadership to harness the millions of scientists and patients, powerful new therapies, and cultural changes needed to double our rate of progress against cancer. 

He will also provide a progress report on the Biden Cancer Initiative which is now continuing this movement to double our rate of progress in preventing, detecting, diagnosing and treating cancer.

This session was presented at the 4th annual Immuno-Oncology 360 conference in February 2018.

For the latest news in immunotherapy, join us at the 5th annual IO360 conference taking place February 6-8, 2019 in New York, NY.

Jeffrey Weber, Deputy Director at Laura and Isaac Perlmutter Cancer Center and Co-director of Melanoma Program and Head of Experimental Therapeutics at NYU Langone Medical Center, discusses the day to day management of, and the science around, IO adverse events that may help us understand how these drugs work. Including:

The need to educate physicians about management of immune related adverse events with increasing penetration of checkpoint inhibitors into the communityThe relationship of these adverse events to outcome with checkpoint inhibitionThe relation of adverse events to other autoimmune diseases that are similar in nature

This session was presented at the 4th annual Immuno-Oncology 360 conference in February 2018.

For more information on the IO360 conference and details for the 5th annual program taking place February 6-8, 2019 in New York, NY, please visit io360summit.com.

The BioCentury Report on Industry Trends covers how companies and academic investigators are driving innovations within immuno-oncology, including new targets, modalities and technologies, to address some of the field's biggest challenges. Some topics include:

The broadening trend to harness the innate and adaptive arms of the immune system for immunotherapiesNew cell types beyond CAR-T and traditional T-cellsCombination strategies for neoantigens and other targets from the earliest stages of drug development

This presentation, presented by Simone Fishburn, PhD, Editor, BioCentury Innovations, was given at the 4th Annual Immuno-Oncology 360° Event on February 7-9, 2018 in New York City.

Find more information at io360summit.com

IO360° brings together science, clinical and business under one roof to accelerate treatments to fight a wider range of cancers. This brief podcast gives you an overview on what you can expect at IO360°.

The three-day summit features 10 plenary sessions with over 80 speakers and includes ten plus hours of networking. There will be over 450 attendees.

Key benefits:

Access to KOLs driving the sciencePartnership opportunities with all stakeholders in Immuno-OncologyPresentations on the latest data affecting the science, clinical and business advancements in Immuno-Oncology

IO360° is chaired by Dr Andrew Baum, Citi along with Dr Axel Hoos, GlaxoSmithKline and Dr James Gulley, National Cancer Institute.

Learn more information about IO360° at www.io360summit.com

Take 10% off the regitration fee with code RADIO

The 8th Annual Partnership Opportunities in Drug Delivery (PODD) event will take place on October 18-19, 2018. PODD is designed with 3 purposes:

To present a strategic level program for pharma and biotech biz development professionals with a thorough overview of the latest drug delivery technologies available along with an update on deals and opportunities.To provide drug delivery with a platform to present their technologies and get the latest insights on what the delivery and formulation needs are.To offer ample networking time, facilities and services for one-on-one meetings to establish new business contacts and enhance existing ones.

PODD is chaired by Dr Barbara Lueckel, Head of Research and Technologies Partnering at Roche. MIT's Dr Robert Langer and Polaris' Amy Schulman, two dynamic entrepreneurs in biotech are the opeining keynotes in a fireside chat. Justin Wright, PhD, Global Head of Innovation, Novartis will provide an industry keynote.  Also, Jeffrey Karp, PhD keynotes with Stories from Bioinspiration to drug delivery. Choice of delivery tech tracks and includes partnering support. More info: theconferenceforum.org

Host: Valerie Bowling, PODD Director

Can you imagine coming from a family of 21 kids in a small remote village in Africa with no running water or electricity and one day a snake bite changes your entire future and you end up a PhD student in WInston-Salem, NC?  In this remarkable story, our guest Goodwell Nzou, PhD candidate in molecular medicine at the Institute at Wake Translation Science tells Valerie Bowling, Executive Director, the Conference Forum how he went from a village kid to an amputee to a band member that led him to a contest, a role in an Oscar winning documentary to a PhD candidate in a field that he hopes one day will allow him to grow back his own leg through regenerative medicine. 

Schools cited in the podcast include:

Jairos Jiri Association 

King George VI Centre

Wake Forest School of Medicine

Guest: Goodwell Nzou, PhD candidate in molecular medicine at the Inst at Wake Translation Science

Host: Valerie Bowling, Executive Director, PharmaTalk Radio and the Conference Forum

Podcast guest, Elise Felicione, who is currently a Scientific Collaborator at the Scripps Translational Science Institute is playing an integral role under the direction of Dr Eric Topol on a nation-wide initiative from the NIH. The initiative is called All Of Us, a US Precision Medicine program that aims to enroll a million Americans and follow them for 10 years, during which time participants will contribute biological, environmental, and lifestyle data.  One-third of participants will participate virtually (not via a research site).  The cohort will mirror the projected 2040 census. Individual pharma companies are never going to create cohorts like this, so the importance of this open source frame work that drug developers can tap into will be highly beneficial in serving the patient of the future.

Discussion points include:

What is the All Of Us Research Program?Why does this matter to biopharmaceutical companies?How far along is the program and how to get invovled?What are your biggest challenges?How can biopharmaceutical companies get involved?

For more information on the All of Us program, visit: https://allofus.nih.gov/

Elise will be speaking at DPharm on September 26th and will also have an exhibit booth to answer any questions are All of Us. For information on DPharm taking place September 25-26, 2018 in Boston. For information, please visit, www.theconferenceforum.org

Producer: Valerie Bowling, Executive Director, Pharma Talk Radio and DPharm

During his graduate work, Dr Benjamine Liu observed the many bottlenecks that get in the way of clinical trials slowing the development of new treatments for patients. This challenge inspired him to launch Trialspark.

Trialspark partners with doctors to create FDA compliant trial sites within their existing practices (like Airbnb), unlocking the 98% of patients and doctors not involved in trials today and democratizing access to research treatments.  In this podcast discussion with Ben, we discuss how to reimagine clinical trials, entrepreneurism, the rise of Trialspark and reducing the barriers for patients and investigators. 

Ben will be speaking at DPharm on September 26th in Boston with Dr Ulo Palm, SVP Global Drug Development Operations, Allergan on a case study to scale more efficient clinical trials.

For more information about Trialspark, visit www.trialspark.com

For more information about DPharm visit www.theconferenceforum.org

Producer: Valerie Bowling, Executive Director, Pharma Talk Radio and DPharm